Observational studyInternational journal of urology : official journal of the Japanese Urological Association2026
The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate-Specific Antigen Levels Below 10 Ng/mL.
Observational study in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo evaluate complementary roles of Prostate Health Index (phi) and multiparametric magnetic resonance imaging (mpMRI) in detection of any prostate cancer (PC) and clinically significant PC (csPC) and to investigate likelihood of risk stratification for recommending prostate biopsy in men with prostate-specific antigen (PSA) ≤ 10 ng/mL.
methodsThis exploratory post hoc analysis of the prospective multicenter PROPHET cohort included 108 Japanese men who underwent prebiopsy mpMRI. All MRI findings were retrospectively reviewed by one specialized radiologist and scored using Prostate Imaging Reporting and Data System (PI-RADS) v2.1. csPC was defined as ISUP grade group (GG) of 2-5. Then, the likelihood of risk stratification for detecting any PC and csPC based on PI-RADS categories and a significant [-2]proPSA-related index assessed by receiver operating characteristic (ROC) analyses was retrospectively investigated.
resultsPC was detected in 51 of 108 men (47.2%). The ROC analyses revealed the superiority of phi in detecting PC and csPC. Among men with phi ≤ 36.0 and PI-RADS 1-3, csPC was detected in 2 of 36 men (5.6%), but no GG 3-5 cancers were observed. In contrast, in men with phi > 36.0, the risk of detecting PC/csPC was 42.9% (9/21)/23.8% (5/21), 42.9% (3/7)/42.9% (3/7), and 89.3% (25/28)/71.4% (20/28) in PI-RADS 1-2, 3, and 4-5, respectively.
conclusionsphi and mpMRI have complementary roles for biopsy decision-making in men with PSA ≤ 10 ng/mL. Men with phi ≤ 36.0 and PI-RADS 1-3 may be candidates for biopsy avoidance, whereas phi > 36.0 may be a high-risk group recommending prostate biopsy regardless of mpMRI findings. REGISTRY AND REGISTRATION NO. OF THE STUDY/TRIAL: This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), registration number UMIN000047187.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.